• In early 2026, Ouster issued first-quarter revenue guidance of US$45 million to US$48 million, ahead of analyst consensus and supported by contributions from its StereoLabs acquisition and a long stretch of consecutive product revenue increases.
• This combination of stronger-than-expected revenue guidance and growing software-attached bookings has intensified investor attention ahead of Ouster’s upcoming May earnings call.
• We’ll now examine how this stronger-than-expected first-quarter revenue guidance could reshape Ouster’s existing investment narrative and risk-reward profile.

We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Ouster Investment Narrative Recap

To own Ouster, you need to believe lidar and “physical AI” can justify continued investment despite ongoing losses, competition and pricing pressure. The stronger first quarter 2026 guidance of US$45 million to US$48 million heightens focus on the May earnings call as the key near term catalyst, while also spotlighting the risk that any miss or softer outlook could quickly revive worries about margin volatility and market share pressure.

The most relevant recent announcement here is Ouster’s report of twelve straight quarters of product revenue growth and doubled software attached bookings in 2025, helped by the StereoLabs acquisition. That context makes the above consensus beating guidance more meaningful, because it ties short term expectations directly to whether Gemini, Blue City and StereoLabs can keep supporting higher value, software rich deals ahead of the earnings call.

Yet against this encouraging setup, you should still be aware of how exposed Ouster is if even one major contract is delayed or scaled back...

Ouster's narrative projects $335.6 million revenue and $30.3 million earnings by 2028.

Uncover how Ouster's forecasts yield a $39.50 fair value, a 91% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts paint a far more cautious picture, assuming roughly US$416 million of revenue and modest profits by 2029, which may look conservative if Ouster’s stronger Q1 outlook and growing software focus eventually prove more durable than those expectations imply.

Explore 9 other fair value estimates on Ouster - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ouster research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Ouster research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ouster's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.